Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2014-06-01 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Circadian's VGX-100 Well Tolerated in Phase 1 Clinical Trial 4 pages 287.9KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement and presentation of clinical trial results for a pharmaceutical product (VGX-100) by Circadian Technologies. It includes clinical trial design, patient demographics, safety and tolerability data, tumor response results, and references to presentations at the American Society of Clinical Oncology (ASCO) annual meeting. The document is lengthy (15,000 characters) and contains substantive clinical and scientific data rather than just an announcement or summary. It is not a financial report, earnings release, regulatory filing, or management discussion. It is a scientific and clinical update related to drug development and trial results, which does not fit into typical financial report categories but is best classified under Regulatory Filings (RNS) as a general regulatory announcement and clinical trial update. There is no indication this is an Annual Report, Interim Report, or any other financial filing type. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2014-06-01 English
Circadian Appoints CFO and Company Secretary 1 page
Board/Management Information Classification · 100% confidence The document is a media release announcing the appointment of a new Chief Financial Officer and Company Secretary. It contains no financial data, no report or filing references, and is focused on management changes. The document length is short (2486 characters), and it is clearly an announcement rather than a report or regulatory filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2014-05-18 English
VGX-100 Phase 1 Study Selected for Presentation at ASCO 2014 2 pages 154.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 15 May 2014 announcing that Ceres Oncology, a subsidiary of Circadian Technologies Limited, has been selected to present Phase I clinical data of VGX-100 at the ASCO 2014 Annual Meeting. The content focuses on the clinical trial details, presentation schedule, and company background. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a public announcement about a clinical data presentation at a conference, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report but rather the upcoming presentation of clinical data. Therefore, the document fits best as a Regulatory Filings (RNS) category, which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2014-05-14 English
Opthea Completes Pre-IND Meeting with FDA 2 pages 131.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 12 May 2014 announcing that Circadian Technologies Limited has completed a pre-IND meeting with the FDA regarding their drug OPT-302 for wet AMD. The content focuses on regulatory interaction, clinical development plans, market potential, and investment risks. There are no financial statements, quarterly or annual results, nor any detailed financial data or management discussion of financial performance. The document is a corporate announcement about a regulatory milestone and clinical development progress, not a financial report or earnings release. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a call transcript, board change, or other specific category. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2014-05-11 English
OPT-302 reduces established wet AMD lesions in the mouse 4 pages 697.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 6 May 2014 from Circadian Technologies Limited about preclinical data on their drug candidate OPT-302 for wet AMD. It discusses scientific results from a mouse model, references a poster presentation at a scientific conference (ARVO 2014), and provides background on the disease and market context. The document is a public announcement of research findings and company plans, not a financial report, regulatory filing, or management discussion. It does not contain financial statements, earnings data, or regulatory certifications. It is a press release focused on scientific and clinical development updates. Therefore, it fits best into the category of a Regulatory Filing (RNS) as a general regulatory announcement and public disclosure that does not fit other specific categories.
2014-05-05 English
CEO Terms of Employment 2 pages 209.8KB
Board/Management Information Classification · 100% confidence The document is a media release announcing the appointment of a new CEO and Managing Director, including details of employment terms such as remuneration and incentives. It references ASX listing rule 3.16.4, which relates to disclosure of director appointments and changes in senior management. There is no financial data, report, or regulatory filing content. The document is clearly about management information and changes in the company's board or senior management.
2014-04-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.